The 6 biotech conferences worth attending before your Series B

Sweden's biotech pipeline has more preclinical programs than Eli Lilly, according to SwedenBIO's most recent annual pipeline report. Most of those programs are running out of pre-Series B companies with no commercial team. The founders leading those companies are making conference decisions based on word-of-mouth and habit, not strategic logic.

This post is for founders and early commercial leaders in Sweden, Denmark, Norway, and Finland who want to know which events are worth the time — and what each one is actually optimized for.

The Nordic life sciences ecosystem in brief

Three clusters dominate the Nordic landscape.

Stockholm-Uppsala is the largest, anchored by Karolinska Institutet and Science for Life Laboratory. It produces a consistent pipeline of academic spinouts, enabled by Sweden's teacher's exemption — a structural rule that lets academic researchers retain ownership of their own IP. This creates an unusually high density of founder-led companies compared to most other biotech regions.

Skåne — and specifically the Medicon Valley region spanning Copenhagen and Malmö-Lund — is the cross-border cluster built around the University of Copenhagen, Lund University, and a network of more than 600 life sciences companies and 9 research universities, according to the Medicon Valley Alliance. It is also the home of Novo Nordisk and its foundation, which has become one of the largest private sources of life sciences funding in Europe.

Gothenburg is the third hub, linked to AstraZeneca's Swedish operations and a cluster of small molecule and oncology companies.

What these three clusters share is a structural funding constraint. Nordic investors are well-equipped to lead rounds up to roughly €15 million, but the capital required to reach clinical milestones often requires foreign syndication — US crossover funds, UK-based life sciences VCs, or pan-European firms. The most recent HSBC Innovation Banking analysis of UK and Nordic venture financing found average deal size in the region increasing 32% year-over-year, driven partly by that syndication dynamic.

This is why conference strategy matters more for Nordic founders than for a company based in Boston or Basel. You are not surrounded by the capital. You have to go to it.

What partnership conversations actually require before the data arrives

Business development at large pharma and mid-sized biotech works on long cycles. The people evaluating your asset in 2027 have been building their watchlist since 2024. They are not browsing the scientific literature looking for surprises. They are tracking companies and programs they've already identified as interesting. You need to be interesting to them before you have anything to sell.

Pharma companies with top-quartile sourcing networks identify licensing targets 6 to 8 months earlier than their competitors, according to Vision Lifesciences' 2026 Biotech Licensing Deal Tracker. That gap compounds: by the time a mid-tier pharma company becomes aware of your program, the strategic players may have already completed initial due diligence and formed a view.

Once formal discussions begin, deals themselves take anywhere from 6 weeks to 12 months to close depending on complexity, according to Novartis's published BD process guidance. The implication is clear: the window for building awareness needs to open well before you think you are ready for partnership conversations.

The 6 conferences that actually move things forward

Not every event on the Nordic calendar is worth your time before Series B. Some are primarily networking within the cluster. Some are science-focused in ways that don't convert to BD conversations. The six below each serve a distinct commercial purpose.

1. Nordic Life Science Days — the regional flagship

Organized by SwedenBIO, Nordic Life Science Days (NLSDays) is the largest annual life sciences event in the Nordic region. The most recent edition drew more than 1,400 delegates from 30 countries, including 150+ investors and 130+ exhibiting companies, with around 3,000 one-to-one meetings scheduled through the partnering platform.

The commercial value is unusually broad-spectrum: this is one of the few events where a pre-Series B founder can access Nordic VCs, European pharma BD teams, and international delegations in the same two-day window. The Nordic Star Pitch Competition adds a visibility layer for earlier-stage companies.

If you attend only one Nordic event per year, this is the one.

2. LSX Nordic Congress — curated partnering in Copenhagen

Run by Informa Connect, the LSX Nordic Congress is smaller and more selective than NLSDays. Attendance is vetted rather than open. It sits in the Copenhagen half of the Medicon Valley region and connects the Nordic and Baltic ecosystems with European and global capital.

The value is in the signal-to-noise ratio. Because attendees are screened, conversations tend to be higher quality and more commercially oriented than at a general ecosystem event. For a founder looking to set up serious investor or BD meetings in advance, the structured format works in your favor.They pick a very small number of channels and maintain them consistently.

Not a blog, a newsletter, a Twitter account, LinkedIn, an events calendar, and a podcast. One or two channels, updated regularly, by people with enough seniority that the content actually carries weight. For most pre-commercial biotechs, this means LinkedIn (specifically the founder or CSO's personal account) and consistent physical presence at four to six high-relevance conferences per year.

The companies that do this well have also built an internal system for it, because consistency without a system collapses the moment the CEO is consumed by an IND filing or a board meeting. The system doesn't need to be elaborate. It needs to be reliable enough that commercial visibility doesn't disappear for six months whenever something important happens in the lab.

3. Bio-Europe — where European pharma BD actually happens

Bio-Europe runs two editions per year and is the largest pharma partnering conference in Europe. The fall edition draws more than 5,800 attendees from 3,200+ companies across 60+ countries. The spring edition generates roughly 20,000 one-to-one meetings per edition.

The mechanism matters. Bio-Europe runs on a structured meeting-scheduling platform called partneringONE. You request meetings in advance, and the conference floor is built around those meetings. This is not a networking event in the informal sense. It is an organized BD calendar compressed into three days.

For Nordic founders at the pre-Series B stage, Bio-Europe is the access point to European pharma BD teams who do not attend the Nordic-specific events — the people actively building their watchlist of programs to evaluate. If you want to be on that list, you need to be in the room.

4. BioStock Life Science Summit — the Swedish early-stage investor event

BioStock is the Swedish life science media and events brand that specifically targets the seed-to-commercial stage. Its annual summit in Lund is positioned as the Nordic region's leading forum for early-stage and growth-phase companies bridging innovation and capital. Attendees include BD representatives from Europe, the US, and Asia, alongside Swedish and international investors.

The Lund location places it in the heart of Medicon Valley. The curated, smaller format makes it distinct from NLSDays in atmosphere: founders tend to get more time per conversation. For a pre-seed-to-Series A company not yet ready for the volume of Bio-Europe, this is a well-calibrated entry point.

5. BioEquity Europe — investor-focused dealmaking

BioEquity Europe, run by EBD Group, is positioned as Europe's premier event for financial dealmakers and biopharma executives. It draws around 1,000+ executives and investors from 30+ countries and is explicitly investor-focused rather than broad pharma BD.

If your primary objective at a given conference is fundraising conversations rather than out-licensing or co-development, BioEquity's format is more precisely built for that than Bio-Europe. SwedenBIO lists it on the standard Nordic conference calendar, and Nordic companies participate consistently.

6. Biotech Showcase during JPM week — the US access point

This one is different from the others: it is not in Europe, and it is not optimized for the Nordic ecosystem. It is included here because it is the highest-density week for global biotech dealmaking, and Nordic founders who want access to US crossover funds, US pharma BD, or investors who do not attend European events have no better single-week alternative.

The JPMorgan Healthcare Conference itself is invite-only and dominated by large-cap companies. Biotech Showcase, run concurrently by EBD Group, is the accessible entry point for earlier-stage companies. The most recent edition drew 3,200+ biopharma leaders and 1,200+ investors, with more than 6,000 one-to-one meetings scheduled.

How many conferences should a pre-Series B Nordic biotech founder attend per year?

Most pre-Series B Nordic founders are best served by attending four to six conferences per year rather than spreading presence thin. Prioritize two or three events with structured partnering platforms, one Nordic-specific event for cluster visibility, and one international event for access to capital and BD networks beyond the region. Follow-up content and relationship maintenance after each event matters more than attendance volume.

What this means for founders without a commercial team

The structural challenge for most pre-Series B Nordic companies is not access to conferences. It is consistency.

A founder can attend Nordic Life Science Days and have twelve good conversations. Then the IND filing takes three months, and the next conference appearance is nine months later. The BD relationships that were warm in September are cold by June.

The companies that convert conference activity into commercial outcomes have built a system for staying visible between events. That means a personal LinkedIn presence publishing consistently, a company page that reflects current pipeline status, and a follow-up process from meetings that does not depend on finding a quiet week.

This is not a technology problem or a budget problem. The most recent SwedenBIO Life Science Barometer identified business development and leadership as the most urgently needed competencies across Swedish life science companies — ahead of clinical, regulatory, and scientific skills. The founders who take conference strategy seriously as a commercial investment tend to be the same ones who have decided not to wait for a commercial hire to solve it.

Conclusion

The six events above are not a guaranteed path to a partnership or a Series B. They are the venues where the right conversations become possible — and where the visibility built through consistent communications and an updated pipeline converts into meetings rather than missed connections.

The founders who show up at Bio-Europe or NLSDays with nothing but a pitch deck and a business card tend to leave with fewer outcomes than the ones who were already a known name before they arrived.

The question worth sitting with before you book the next flight: what will the people you most need to meet already know about you?

Sources:

• SwedenBIO Annual Drug Development Pipeline Report — press.swedenbio.se

• SwedenBIO Life Science Barometer — nordiclifescience.org

• Medicon Valley Alliance ecosystem data — mva.org

• HSBC Innovation Banking, UK and Nordic venture financing report — hsbcinnovationbanking.com

• Nordic Life Science Days — nlsdays.com

• Bio-Europe — informaconnect.com/bioeurope

• LSX Nordic Congress — informaconnect.com/lsx-nordic-congress

• BioStock Life Science Summit — biostock.se

• BioEquity Europe — informaconnect.com/bioequity-europe

• Biotech Showcase — informaconnect.com/biotech-showcase